Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02108210
Other study ID # R0002198
Secondary ID 2013-005466-19NL
Status Completed
Phase Phase 2/Phase 3
First received March 21, 2014
Last updated May 24, 2016
Start date June 2014
Est. completion date May 2016

Study information

Verified date April 2016
Source Radboud University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Rationale: Chronic fatigue syndrome (CFS) is a medically unexplained syndrome for which no somatic or pharmacological treatment has been proven effective. Dysfunction of the cytokine network has been suspected to play a role in the pathophysiology of CFS. Although derangements of the cytokine network in CFS are controversial, a major problem is that many studies did not use adequate controls. In addition, all studies have been performed on peripheral venous blood of the patients. As cytokines mainly act in the tissues, e.g., the brain, the information that can be derived from peripheral blood cells is limited. The only information regarding the possible role of cytokines in the pathophysiology of CFS could come from intervention studies in which pathogenetically important cytokines are inhibited. A potentially relevant cytokine which can be blocked in humans without severe side effects is IL-1. Although it is plausible that these cytokines play a role in CFS, there is limited evidence for this.

Objective: To investigate the effect on symptomatology of interference with IL-1 in CFS patients.

Study design: A randomized placebo controlled study will be performed to determine whether interference with IL-1 is able to reduce fatigue and disabilities in CFS patients.

Study population: Female CFS patients without psychiatric co-morbidity will be included in this study. Patients of the outpatient clinic of the Department of General internal medicine and the Expert Centre for Chronic Fatigue (ECCF) will be asked to participate in the study. Patients will be asked to bring a healthy neighbourhood control to their first study visit.

Intervention: After inclusion patients will be randomized to receive one of the following treatments:

- interleukin-1 inhibitor Anakinra (IL-1Ra) for 4 weeks (N=25);

- placebo for 4 weeks (N=25).

Main study parameters/endpoints: The primary outcome measure will be fatigue severity measured with the Checklist Individual Strength (CIS) at 4 weeks, measurement will be repeated up to 26 weeks.

Secondary outcome measures will be:

- level of functional impairment measured with the Sickness Impact Profile (SIP8) total score;

- physical and social functioning assessed with the subscale physical functioning and social functioning of the SF-36;

- level of psychological distress assessed with the total score on the Symptom Checklist-90 (SCL-90);

- pain severity assessed with a Visual Analog Scale (VAS);

- cytokine measurement in blood (plasma and blood in Pax-gene tubes) and saliva (at protein and mRNA level);

- cortisol measurement in saliva and hair;

- microbiome determination in faeces;

- body temperature and pulse rate.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date May 2016
Est. primary completion date December 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 59 Years
Eligibility Inclusion Criteria:

- CDC-diagnosed CFS-patients;

- female, between 18 and 59 years old;

- fatigue duration =10 years, or significant increase of complaints during the last 10 years

- score of =40 on the subscale fatigue severity of the CIS (Checklist Individual Strength);

- marked functional impairment assessed with the Sickness Impact Profile (SIP-8) and operationalised as a total score of =700.

Exclusion Criteria:

- pregnant or nursing women;

- women who intend to get pregnant during the study;

- fatigue duration >10 years;

- patients who use or have used psychotropic medication in the past month;

- substance abuse in the past 3 months;

- patients taking any medication except oral contraceptives and/or paracetamol;

- patients with evident somatic co-morbidity;

- previous or current engagement in CFS research;

- inability to understand the nature and the extent of the trial and the procedure required;

- psychiatric co-morbidity (major depression, psychosis, eating disorders, anxiety disorders, bipolar disease and post traumatic stress disorder) assessed with the MINI;

- live vaccination during the past four weeks;

- current engagement in a legal procedure with respect to disability claims.

Study Design


Intervention

Drug:
Anakinra

Placebo


Locations

Country Name City State
Netherlands RadboudUMC Nijmegen Gelderland

Sponsors (1)

Lead Sponsor Collaborator
Radboud University

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Body temperature 4 weeks, measurement will be repeated up to 26 weeks
Other pulse rate 4 weeks, measurement will be repeated up to 26 weeks
Primary CIS (checklist individual strength, compared to baseline) To investigate the role of the cytokine IL-1 in the pathogenesis of CFS and to find leads for future treatment of CFS, a disorder for which there is no proven effective drug treatment. The primary outcome measure will be fatigue severity at 4 weeks measured with the Checklist Individual Strength (CIS). 4 weeks, measurement will be repeated up to 26 weeks
Secondary SIP8 (sickness impact profile, change from baseline) level of functional impairment 4 weeks, measurement will be repeated up to 26 weeks
Secondary SF-36 (subscale physical functioning and social functioning, compared to baseline) physical and social functioning assessed with the subscale physical functioning and social functioning of the SF-36 4 weeks, measurement will be repeated up to 26 weeks
Secondary SCL-90 (symptom checklist-90, compared to baseline) level of psychological distress assessed with the total score on the Symptom Checklist-90 4 weeks, measurement will be repeated up to 26 weeks
Secondary VAS pain (visual analog scale, compared to baseline) pain severity assessed with a Visual Analog Scale 4 weeks, measurement will be repeated up to 26 weeks
Secondary Cortisol in saliva and hair (concentration compared to baseline) Because of the possible role of the hypothalamus-pituitary-adrenal axis we will also measure the cortisol concentration in saliva and hair. For the baseline assessment, comparison will be made with matched neighbourhood controls. 4 weeks
Secondary microbiome determination faeces A new field of great interest in pathophysiology is the role of the microbial flora of the host (microbiome). The availability of well defined patients with CFS and matched controls is a great opportunity in an unexplored area of CFS research, to assess whether the microbiome of CFS patients is peculiar. at baseline
Secondary cytokine concentrations in blood and saliva (compared to baseline) In addition to the cytokine intervention, we will assess cytokines (at the transcriptional level and as proteins) in serum and saliva at baseline and after 4 weeks of intervention. For the baseline assessment, comparison will be made with matched neighbourhood controls. 4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05454683 - Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome N/A
Completed NCT01686074 - Motor Control in Chronic Fatigue Syndrome and Fibromyalgia N/A
Completed NCT02075489 - Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans N/A
Completed NCT01651754 - Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome N/A
Completed NCT00540254 - Behavioral Insomnia Therapy With Chronic Fatigue Syndrome Phase 1/Phase 2
Active, not recruiting NCT00071162 - Genetics of Fibromyalgia N/A
Withdrawn NCT04870476 - Feasibility and Acceptability of the Internet-delivered Treatment "One Step at the Time" for Bodily Distress Syndrome N/A
Completed NCT05730660 - Quercetin Phytosome® Chronic Fatigue Syndrome N/A
Recruiting NCT04542161 - Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Phase 2
Recruiting NCT03807973 - Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes. Phase 1
Recruiting NCT05719493 - Effectiveness and Health Benefits of a Nutritional, Chronobiological and Physical Exercise Intervention in Fibromyalgia and Chronic Fatigue Syndrome (SYNCHRONIZE +) N/A
Recruiting NCT05967052 - Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation Phase 2
Terminated NCT01730495 - Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome Phase 2
Completed NCT01156909 - B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome Phase 2
Completed NCT01650636 - Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process N/A
Completed NCT01046370 - A Pilot Study of Amygdala Retraining Program in Patients With Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia N/A
Completed NCT00100412 - Hyporeactivity and Gulf War Illness N/A
Recruiting NCT06128967 - A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial Phase 3
Completed NCT02669212 - Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health N/A
Not yet recruiting NCT06011135 - Exploring Worry in CFS/ME